UBC® Rapid is a powerful Doctors-office test (Point-of-Care), for both primary diagnosis and follow-up of bladder cancer, especially for non-invase high-grade tumors and carcinoma in sity (CIS). One clear advantage is that UBC®Rapid can be performed immediately and the result will be available during the patient visit. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. Elevated amounts of cytokeratin protein fragments are present in the urine of many individuals with bladder cancer, even at early stages of the disease. UBC® Rapid shall be used for quantitative determination in combination with the POC-reader, concile® Ω100.
– The only quantitative POC test platform for urine based detection of bladder cancer. – Easy and rapid to perform – result within 10 minutes – Works in haematuria
Clinical evaluation UBC® Rapid performs better than urine cytology in many patients due to improved sensitivity and the combination of UBC® Rapid and cytology enables detection of additional tumors as opposed to cytology alone.
The tumor marker TPS® is a reliable indicator of tumor cell activity particularly useful in patient managementfor different carcinomas. Compared with conventional tumor mass markers, the activity marker TPS® provides the clinician with earlier signals about the course of the disease. TPS® is particularly useful in treatment monitoring and surveillance of patients with epithelial cell carcinomas e.g. breast, prostate and ovarian cancer. Clinical evaluation TPS® is a quantitative immunoassay that specifically measures a defined epitope on cytokeratin 18. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum and plasma. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity. By following the patient with repeated assays of TPS® , both during treatment and at follow up, the clinician obtain critical information about the tumor activity during surveillance for early detection of recurrence. Available in ELISA and IRMA formats.
MonoTotal® is a sensitive tumor activity marker for detection and identification of Non-small Cell Lung Cancer (NSCLC). By using MonoTotal®, the physicians receive an early indication of disease status, measured in terms of tumor cell activity rather than more conventional tumor burden measurements. MonoTotal®provides the physician with a reliable monitoring aid for disease progression and treatment in lung cancer patients. MonoTotal® is a quantitative immunoassay that specifically measures defined epitopes on cytokeratin 8, 18 and 19. The test result is directly proportional to the concentration of soluble cytokeratin fragments in serum. An elevated level of soluble cytokeratin fragments in patient samples is an indication of epithelial tumor cell activity.
Clinical evaluation MonoTotal® correlates well with tumor cell activity and the extent of the disease. Studies published during the last years shows that MonoTotal®has a strong association with clinical response in patients. MonoTotal®demonstrates high sensitivity in patients with NSCLC, independent of histotype. The overall sensitivity is about 70-75%, at 95% specificity and correlates well with tumor cell activity and the extent of the disease.
TUBEX® TF is a rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonellaenterica serovarTyphi . The test principle is based on Inhibition Magnetic Binding Immunoassay (IMBI®) technology - a semiquantitative colometric assay. A positive TUBEX® TF result, together with typical clinical symptoms, is a strong indication of acute typhoid fever. TUBEX® TF can easily be performed in any laboratory setting as well as in the field and the result is ready within 10 minutes.
TUBEX® TF Wash is a new product which enables analysisof colored samples (icteric, haemolytic). All components, including the wash buffer, are included in the kit.
UBC® II ELISA is a quantitative in vitro diagnostic assay for aid in diagnosis, for prognosis and follow-up of bladder cancer patients. It measures soluble fragments of cytokeratin 8 and 18 in human urine samples. UBC® II ELISA is particularly useful for follow-up checks for recurrence of disease in patients with earlier diagnosed bladder cancer and for aid in diagnosis in patients with suspected bladder cancer. Bladder cancer has one of the highest rates of recurrence. Tests for early detection and patient monitoring are crucial. Studies have shown that UBC® is a useful marker for clinical management of bladder cancer patients. UBC® demonstrates high diagnostic sensitivity in low-stage and low-grade bladder tumors (Tis, Ta and T1).
Provides knowledge to decision IDL Biotech is a diagnostic company that develops, produces, and markets In Vitro Diagnostic (IVD) tests worldwide for the health care sector. We are active in the fields of oncology and bacteriology through manufacturing of various tumor markers and a rapid Salmonella typhoid test. IDL Biotech AB (publ) is a public company listed on the Swedish equities market place, Spotlight Stock Market
IDLs products enable disease diagnosis and prognosis, control of treatment efficiency, and prolong the interval between more invasive patient examinations.
We are located just outside Stockholm, Sweden, where all company functions, including management, sales & marketing, orders & shipping, R&D, production, and quality assurance can be found.
IDLs products are distributed primarily in Europe and Asia through a network of international business partners.
Our history In 1988, IDL was founded under the name IDL Immuno Develop Lab. 10 years later the company name was changed to IDL Biotech AB (publ). IDL Biotech AB (publ) has been listed on the Swedish equities market place, Spotlight Stock Market, since 1999.